Economic evaluation in cardiology; background and application;Economische evaluatie binnen de cardiologie; achtergrond en toepassing

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 38, 1998, Pages 2083-2086

  Van Hout, B A ^a   Goes, E S ^a   Grijseels, E W M ^a   Quarles Van Ufford, M A ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Medisch Centrum de Klokkenberg   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MATHEMATICAL MODEL; REVIEW;

CARDIOLOGY; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; NETHERLANDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS;

EID: 0032547484     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Nederlandse Hartstichtung. Hart- en vaatziekten in Nederland 1996 cijfers over ziekte en sterfte Den Haag: Nederlandse Hartstichung, 1996.
2. Rijksinstituut voor Volksgezondheid en Milieu. Volksgezondheid Toekomst Verkenning 1997. De som der delen Utrecht. Elsevier/De Tijdstroom, 1997.
3. Polder JJ, Meerding WJ, Koopmanschap MA, Bonneux L, Maas PJ van der. Kosten van ziekten in Nederland 1994; grootste zorgverbruik door hoge leeftijd en beperkende aandoeningen. Ned Tijdschr Geneeskd 1998;142:1607-11.
4. Hout B van, Bonsel G, Habbema D, Maas P van der, Charro F de, Heart transplantation in the Netherlands: costs, effects and scenarios. Journal of Health Economic 1993;12:73-93.
5. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6
6. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J 1996;17.1001-7.
7. Martens LL. The cost-effectiveness of cholesterol-lowering therapy with simvastatin in the primary prevention of coronary heart disease in the Netherlands [proefschrift]. Rotterdam: Erasmus Universiteit Rotterdam, 1992.
8. Bergen PFMM van, Jonker JJC, Hout BA van, Domburg RT van, Deckers JW, Azar AJ, et al. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 1995; 273:925-8.
9. Hout BA van, Wielink G, Bonsel GJ, Rutten FFH. Effects of ACE inhibitors on heart failure in the Netherlands: a pharmacoeconomic model, PharmacoEconomics 1993;3:387-97.
10. Michel BC, Al MJ, Remme WJ, Kingma JH, Kragten JA, Nieuwenhuizen R van, et al. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in the Netherlands. Eur Heart J 1996;17:731-40.
11. Hout BA van, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for the Netherlands. Eur Heart J 1995;16(Suppl L):81-5.
12. Hout BA van, Bowman L, Zelinger DJ, Simoons ML. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. Am Heart J 1998;135:S98-106.
13. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. York. UK: Oxford University Press, 1997.
14. Rutten FFH, Busschbach JJ van, Hout BA van, Koopmanschap MA, Michel BC. Economische evaluatie van gezondheidszorgprogramma's: principes en Instrumentarium. TSG 1998;76:74-82.
15. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy (Elsevier) 1990; 16:199-208.
16. Koopmanschap MA, Rutten FFH. Berekening van kosten van zorg; vaak onderschat in economische evaluatiestudies. TSG 1998;76:83-8.
17. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
18. Serruys PW, Jaegere P de. Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
19. Hout BA van, Woude T van der, Jaegere PPT de, Brand M van den, Es GA van, Serruys PW, et al Cost effectiveness of stent implantation versus PTCA: the BENESTENT experience. Semin Interv Cardiol 1996;1:263-8
20. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost effectiveness in health and medicine. New York. Oxford University Press, 1996.
21. Boer MJ de, Hout BA van, Liem AL, Suryapranata H, Hoorntje JCA, Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol 1995;76:830-3.
22. Simoons ML, Casparic AF. Behandeling en preventie van coronaire hartziekten door verlaging van de serumcholesterolconcetratie; derde consensus 'Cholesterol'. Ned Tijdschr Geneeskd 1998;142: 2096-101.
23. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9
24. Sacks FM, Pfeffer MA, Move LA, Rouleau JL, Rutherford JD, Cole TG, et al The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9
25. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesteroleima. N Engl J Med 1995;333:1301-7.
26. Casparic AF, Everdingen JJE van, Grol RPTM, Klazinga NS, Kleijnen J, Loo M van het, et al. Ontwikkeling en implementatie van kosteneffectieve richtlijnen. Med Contact 1998;53:88-90.
27. Bruijn EM de, Klazinga NS, Dillmann RJM. Passend kiezen in de gezondheidszorg. Med Contact 1998;53:586-9.